2015
Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions: A More Accurate Assessment of Readmission
Tosoian JJ, Hicks CW, Cameron JL, Valero V, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, Weiss MJ, Wolfgang CL. Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions: A More Accurate Assessment of Readmission. JAMA Surgery 2015, 150: 152-158. PMID: 25535811, PMCID: PMC4461067, DOI: 10.1001/jamasurg.2014.2346.Peer-Reviewed Original ResearchConceptsTertiary care referral centerPatient-level factorsNonindex hospitalEarly readmissionReferral centerMultivariable analysisPatterns of readmissionPostoperative drain placementRate of readmissionRisk of readmissionData of patientsAge 65 yearsHigh-volume institutionsDistal pancreatectomyPostoperative infectionPrimary outcomeLiver diseaseDrain placementInstitutional databaseRisk factorsPancreatectomyRetrospective analysisReadmissionMAIN OUTCOMEPatients
2013
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study.
Azad N, El-Khoueiry A, Mahoney M, Adkins D, Flynn P, Bahary N, Kim G, Pitot H, Erlichman C, Donehower R, Herman J, Baylin S, Ahuja N. A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. Journal Of Clinical Oncology 2013, 31: 3539-3539. DOI: 10.1200/jco.2013.31.15_suppl.3539.Peer-Reviewed Original ResearchMetastatic colorectal cancerPrior regimensGood end-organ functionCombination epigenetic therapyECOG PS 0End-organ functionPhase II studyUrinary tract obstructionSerial tumor biopsiesInitial eligibility criteriaCRC cell linesMulti-institutional studyMCRC ptsChest painPrimary endpointPrior therapyRECIST criteriaTract obstructionII studyPS 0Cohort BCohort ALiver diseaseSubsequent therapyColorectal cancer